Home


COVID-19: CARB-X remains open for business – virtually

CARB-X staff members are working from home. We continue to make payments to support the research programs in our portfolio, and will announce new awards as they are approved and contracts finalized.

Even as we struggle with the COVID-19 pandemic, it is critical that we continue to support the development of innovative antibiotics and other therapeutics, vaccines and diagnostics to address drug-resistant bacteria.

 


CARB-X is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines. Since CARB-X was established in July 2016, it has invested $252.7 million in 70 projects around the world.

256.6

$million

Invested

71

innovative

Projects

10

different

Countries

18

focused on new classes

Pipeline

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address the emergence of drug-resistant superbugs.
Learn More


Spotlight on Science

UC San Diego spinout Cellics Therapeutics is developing macrophage cellular nanosponges designed to soak up sepsis-causing toxins

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.

Funders

ASPR
BARDA
WellcomeTrust
NIAID
UK Government

Alliance Partners

Bill and Melinda Gates Foundation

Accelerators and other partners

Events

Events

11.05.20

 

Antimicrobial Resistance Fighter Coalition Webinar: Aiming in the dark: what happens when disease spreads without diagnosis

11.16.20

 

FDA Public Workshop: Potential Approach for Ranking of Antimicrobial Drugs According to Their Importance in Human Medicine: A Risk Management Tool for Antimicrobial New Animal Drugs

11.17.20

 

Live Webinar: GARDP/REVIVE – Discovery of new antibacterials using artificial intelligence (computational chemoinformatics)

CARB-X News

  • 10.21.2020  |  CARB-X is funding Cellics Therapeutics to develop a novel macrophage nanosponge to prevent and treat sepsis full release

  • 10.20.2020  |  CARB-X 2019-20 Annual Report: Record high awards and funding during its fiscal year in the race against drug-resistant bacteria full release

  • 10.14.2020  |  CARB-X is funding Polyphor to develop a new antibiotic to treat multidrug-resistant Enterobacteriaceae Gram-negative bacterial infections full release

See All News

In The News

  • 10.26.2020  |  Why big pharma has abandoned antibiotics full story

  • 10.23.2020  |  Improving data sharing to increase the efficiency of antibiotic R&D full story

  • 10.16.2020  |  Stuck in the 1950s: why UTI diagnosis badly needs an update full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.